RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07811752, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Have histologically or pathologically confirmed esophageal squamous cell carcinoma (ESCC) that is assessed as unsuitable for definitive treatment modalities (including definitive chemoradiotherapy and/or surgery) according to the American Joint Committee on Cancer (AJCC) TNM Staging System, 9th Edition.

    Inclusion criterion 3

  3. For women of childbearing potential and men with partners of childbearing potential, agree to use highly effective contraception from signing the informed consent form until 6 months after the last dose of study treatment.

    Inclusion criterion 13

    Prior treatment with any TROP2-targeted therapy and/or topoisomerase I inhibitors.

    Exclusion criterion 4

    Any of the following events during prior first-line treatment with a PD-1/PD-L1 inhibitor:

    Exclusion criterion 5

  4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

    Inclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07811752, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Have voluntarily signed a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
  • Be aged ≥18 years, regardless of sex.
  • Have histologically or pathologically confirmed esophageal squamous cell carcinoma (ESCC) that is assessed as unsuitable for definitive treatment modalities (including definitive chemoradiotherapy and/or surgery) according to the American Joint Committee on Cancer (AJCC) TNM Staging System, 9th Edition.
  • Have previously received first-line systemic therapy consisting of an immune checkpoint inhibitor in combination with chemotherapy and have experienced radiographically confirmed disease progression during or after such treatment.
  • Have at least one measurable lesion as defined by RECIST version 1.1, as assessed by the investigator, which has not been previously treated with radiotherapy.
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Have a life expectancy of at least 12 weeks.
  • Have adequate organ and bone marrow function, without receiving blood transfusion, recombinant human thrombopoietin, or colony-stimulating factor treatment within 2 weeks prior to the first dose, as defined by all of the following laboratory criteria:
  • Hematologic function:

Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L.

  • Hepatic function:

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); For subjects with baseline liver metastases, AST and ALT ≤ 5 × ULN; Serum albumin ≥ 30 g/L; Total bilirubin (TBIL) ≤ 1.5 × ULN.

  • Renal function:

Creatinine clearance ≥ 50 mL/min, calculated using the Cockcroft-Gault formula.

  • Coagulation function:

International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) ≤ 1.5 × ULN.

  • For women of childbearing potential and men with partners of childbearing potential, agree to use highly effective contraception from signing the informed consent form until 6 months after the last dose of study treatment.
  • Be willing and able to comply with all protocol-specified visits, treatment plans, laboratory tests, and other study procedures, and voluntarily participate in the study by providing written informed consent.

Exclusion Criteria:

  • Prior placement of an esophageal or tracheal stent.
  • Presence of a high risk of bleeding or perforation due to obvious tumor invasion into adjacent organs of the esophageal lesion (e.g., aorta or trachea), or the presence of a fistula.
  • Participation in another interventional drug clinical trial within 4 weeks prior to enrollment.
  • Prior treatment with any TROP2-targeted therapy and/or topoisomerase I inhibitors.
  • Any of the following events during prior first-line treatment with a PD-1/PD-L1 inhibitor:

1)Disease progression within 3 months after initiation of treatment; History of Grade ≥3 treatment-related adverse events, Grade 2 immune-related cardiotoxicity, or any grade neurologic or ophthalmologic adverse events related to PD-1/PD-L1 inhibitors; 2)Any adverse event from prior PD-1/PD-L1 inhibitor therapy that had not completely resolved or had not improved to Grade 1 or below before study screening; 3)History of adverse events requiring immunosuppressive treatment other than corticosteroids.

6.History of another malignancy within 5 years prior to enrollment, except for adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, or cutaneous squamous cell carcinoma.

7.Known hypersensitivity to any study drug or any of its excipients.

8.Positive test for human immunodeficiency virus (HIV), history of acquired immunodeficiency syndrome (AIDS), or known active syphilis infection.

9.Active autoimmune disease requiring systemic treatment within 2 years prior to initiation of study treatment, or autoimmune disease considered by the investigator to have a risk of recurrence or require future treatment.

10.History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.

11.Receipt of a live vaccine within 30 days prior to the first dose of study treatment.

12.Any of the following pulmonary conditions:History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring corticosteroid treatment; Current ILD or non-infectious pneumonitis;Suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging at screening;Clinically significant pulmonary impairment due to concurrent pulmonary diseases, including but not limited to pulmonary embolism within 3 months prior to first dosing, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, or autoimmune/connective tissue/inflammatory diseases involving the lungs (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis);Prior pneumonectomy.

13.Active autoimmune disease that required systemic treatment within the previous 2 years. Hormone replacement therapy is not considered systemic treatment, including:Type 1 diabetes mellitus;Hypothyroidism requiring only thyroid hormone replacement therapy;Adrenal or pituitary insufficiency requiring only physiologic corticosteroid replacement therapy.

14.Active infection requiring systemic therapy within 2 weeks prior to the first study dose.

15.Any severe concomitant disease that, in the investigator's judgment, may compromise subject safety or interfere with study participation, including but not limited to uncontrolled hypertension, severe diabetes mellitus, or active infection.

16.Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disorders that may delay corneal healing.

17.Women who are pregnant or breastfeeding; women of childbearing potential with a positive pregnancy test at baseline; or women of childbearing potential unwilling to use highly effective contraception during study treatment and for 6 months after the last dose of study treatment.

18.Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT07811752, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07811752, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07811752